HC Wainwright & Co. Maintains Buy on Harpoon Therapeutics, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has maintained a Buy rating on Harpoon Therapeutics (NASDAQ:HARP) and increased the price target from $7.5 to $12.

December 13, 2023 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst has reiterated a Buy rating on Harpoon Therapeutics and raised the price target to $12, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and can lead to increased investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100